Literature DB >> 11533080

Long term recovery of IgG and IgM production during HIV infection in a patient with common variable immunodeficiency (CVID).

S Jolles1, M Tyrer, M Johnson, D Webster.   

Abstract

AIMS: Common variable immunodeficiency (CVID) is the most common serious primary immunodeficiency. This paper describes the immunological consequences of human immunodeficiency virus (HIV) infection in a patient with familial CVID subsequently treated with highly active antiretroviral therapy (HAART).
METHODS: Serial measurements over 11 years of serum immunoglobulins, specific antibodies to tetanus toxoid and pneumococcal polysaccharides, lymphocyte phenotypes, and HIV viral load were made.
RESULTS: The patient recovered total serum IgG and IgM, but not IgA production, with adequate concentrations of specific antibodies, allowing withdrawal of intravenous immunoglobulin without an increase in infections. T cell numbers gradually declined and the patient developed a high grade B cell lymphoma. After successful chemotherapy, HAART was commenced, viral load fell from 472 000 to < 50 copies/ml, and CD4+ T cell numbers increased from 13 to 661 x 10(6)/litre. Antibody production was maintained after suppression of viral load.
CONCLUSIONS: This is the first definitive report of reversal of IgG and IgM deficiency in familial CVID after HIV infection. Failure to normalise IgA supports the concept of separate predisposing genetic factors for selective IgA deficiency, which when combined with others lead to CVID. Furthermore, a persistently high viraemia is not required to maintain the recovery of immunoglobulin values, suggesting this depends either on a transitory effect of a high viral load, or a persistence of low amounts of virus.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11533080      PMCID: PMC1731525          DOI: 10.1136/jcp.54.9.713

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  3 in total

Review 1.  Therapeutic strategies in common variable immunodeficiency.

Authors:  W A Carrock Sewell; Matthew Buckland; Stephen R A Jolles
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 2.  Common variable immunodeficiency and the gastrointestinal tract.

Authors:  Ishaan Kalha; Joseph H Sellin
Journal:  Curr Gastroenterol Rep       Date:  2004-10

Review 3.  Recurrent Sinopulmonary Infections in a Patient Whose HIV Masked Common Variable Immunodeficiency.

Authors:  D Gollapudi; M O'Donnell; M NeSmith; K Kent; A J Hunter
Journal:  J Gen Intern Med       Date:  2020-01       Impact factor: 5.128

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.